Patients with cystic fibrosis (CF), who have signs and symptoms of maldigestion due to pancreatic insufficiency, will require pancreatic enzyme therapy with meals and snacks. Often the diagnosis of CF is established as a direct or indirect result of pancreatic failure. Almost 50% of patients are diagnosed before the age of 1 year and 85% before the age of 5 years. Failure to thrive, frequent loose or bulky stools, rectal prolapse or the triad of hypoalbuminaemia, oedema and anaemia in an infant should suggest the diagnosis. Frequently, however, signs and symptoms of CF are quite subtle: at clinical presentation the phenotypic stereotype of a clinically wasted child with a protuberant abdomen, ravenous appetite, persistent cough and loose frequent stools applies to a relatively small number of patients. Approximately 15% of patients possess sufficient exocrine pancreatic function to absorb nutrients normallyl. Although 'pancreatic sufficient' patients are often said to have normal pancreatic function, quantitative assessment by sophisticated intubation studies demonstrate that the majority possess impaired pancreatic ductal (fluid and electrolyte) and acinar (enzyme) secretion2'3. These studies also confirm the large reserve capacity of the exocrine pancreas: steatorrhoea due to pancreatic insufficiency is present when patients lose more than 98-99% of residual exocrine pancreatic function. Patients with pancreatic sufficiency possess enzyme secretion ranging from the lower limits of the reference range to values marginally above the threshold for developing steatorrhoea.
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Following introduction of neonatal screening programmes, it has become apparent that a considerably higher percentage of pre-symptomatic infants with CF are pancreatic sufficient in early infancy4. However, pancreatic insufficiency develops in most of these patients within the first few years of life.
CLINICAL TESTS OF PANCREATIC FUNCTION
Exocrine pancreatic function is difficult to assess because the pancreas and its secretions are anatomically inaccessible5.
Nevertheless, provided the limitations of existing clinical tests are understood, they can be of considerable help in the initial assessment and ongoing care of patients with CF. Pancreatic function tests may be categorized into three general groups (Table 1) .
Direct tests Direct tests are used to measure pancreatic secretions, either following stimulation of the pancreas using exogenous hormonal secretogogues (secretin, cholecystokinin, etc.) or by endogenous nutrients (Lundh meal, fatty acids, amino acids, etc.). All direct tests are invasive since they necessitate nasointestinal intubation. Successful evaluation of pancreatic secretions is contingent upon stimulating both acinar and ductal secretions, excluding gastric secretions and quantitatively aspirating pancreatic secretions3'6. Unfortunately, no activity21. A synthetic compound (N-benzoyl-L-tyrosylpara-aminobenzoic acid) is cleaved by pancreatic chymotrypsin within the intestinal lumen releasing the marker para-aminobenzoic acid (PABA). PABA is readily absorbed, conjugated in the liver and excreted in the urine. In the conventional test, a 6-h urine collection is performed and the urinary excretion of ingested PABA is determined22. In patients with CF, PABA measured in plasma is more reliable and avoids the difficulty of a lengthy urine collection23 24. Bentiromide can only identify patients with marked loss of pancreatic function. Falsely abnormal tests, have been reported in patients with intestinal, hepatic or renal disease due to abnormalities of absorption, conjugation or excretion of PABA. To correct for these abnormalities, a two-stage test has been proposed by first giving bentiromide then an equivalent dose of free PABA. Alternatively, Bentiromide may be given together with another substance such as para-aminosalisylic acid. Unfortunately, bentiromide is no longer commercially available in most countries.
Blood tests
Immunoassays have been developed which are capable of measuring nanogram quantities of pancreatic enzymes or pancreatic hormones in the circulation (see Table 1 ). In CF, immunoassays for pancreatic trypsinogen and lipase have been most extensively evaluated25--27. These tests rely upon the assumption that the level of circulating enzyme and/or hormone reflect exocrine pancreatic reserve. Unfortunately, due to the obstructive nature of pancreatic pathology in CF, this assumption does not hold true. It We have used 72-h fat balance studies to evaluate the response to enzyme therapy in patients suspected of persistent nutrient maldigestion. Figure 4 shows the results of 240 faecal fat balance studies performed in CF patients with pancreatic insufficiency who were receiving pancreatic enzymes in doses that the patient and/or caregiver considered to be appropriate. Enzyme doses generally conformed to the guidelines recommended by the recently published consensus committee report of the US CF Foundation and the Food and Drug Administration30. It should be emphasized that the patients we studied are not representative of the entire clinic population, because clinical evaluation was limited to those with subjective evidence of a poor response to enzyme therapy, such as abdominal bloating and/or pain, bulky malodorous stools and/or evidence of growth failure. In this patient cohort, enzyme therapy came close to correcting nutrient maldigestion (faecal fat losses less than 10% of intake) in only one-third of patients; in another third, fat losses were moderately severe (11-20% of intake), while fat losses were considerably higher, ranging from 20% to more than 70% of fat intake, in the remaining third.
None of the current enzyme preparations achieve the ideal clinical objectives of therapy which are to * Correct macronutrient maldigestion * Correct micronutrient maldigestion * Eliminate abdominal symptoms attributable to maldigestion * Sustain normal growth and nutritional status on a normal diet
In comparison to patients with pancreatic insufficiency due to other aetiologies, CF patients are particularly difficult to treat. A variety of related and unrelated factors, which are listed in Table 2 , may contribute to the lack of success of enzyme therapy. Additional, poorly understood factors may contribute to the poor response of existing commercial products. Assessment of response in the individual CF patient with pancreatic insufficiency, therefore, necessitates insight into the variables that may influence efficacy. These include the pharmaceutical and biological properties of the various enzyme products, issues concerning patient compliance and a variety of host factors within the gastrointestinal tract, the pancreas and the hepatobiliary system.
Pancreatic enzyme products
Pancreatic enzyme extracts primarily of porcine origin have been used since the 1930s to treat maldigestion due to pancreatic insufficiency. Marketed enzymes include conventional products and various forms of encapsulated enzymes coated by an acid resistant film. Most conventional enzyme preparations consist of desiccated porcine pancreatic extracts enclosed in gelatin capsules. The enteric coated forms vary considerably in their biochemical coating, their Direct pancreatic function studies of adult patients with chronic pancreatitis or CF suggest that approximately 28 000-30 000 units of lipase must be delivered to the proximal intestine to eliminate steatorrhoea3,6. This estimate, which is based upon the observation that between 3-10% of mean stimulated endogenous pancreatic lipase is required to prevent steatorrhoea, assumes the intraluminal environment of the CF intestine is the same as in health. Although this assumption is almost certainly incorrect, simply increasing the dose of enzyme is unlikely to correct the problem of maldigestion. Patients with pancreatic insufficiency tend to have gastric acid hypersecretion and due to pancreatic pathology, there is a relative deficiency of bicarbonate secretion from the pancreaticobiliary tree. Thus, patients with pancreatic insufficiency are likely to possess a more acidic proximal intestine than healthy subjects4. In health, a cyclic adenosine monophosphate (cAMP)-mediated chloride channel, the CF conductance regulator protein (CFTR) is expressed on the apical surface of epithelial cells lining the small pancreatic and biliary ducts. Secretin mediates cAMP induced chloride secretion, and chloride-bicarbonate exchange induces secretion of an alkaline rich fluid which enters the duodenum. In CF, due to the absence of CFTR (or its dysfunction), both chloride and bicarbonate secretion is deficient2. This secretory defect leads to reduced fluid secretions and a further impairment in the ability of pancreaticobiliary secretions to neutralize the acid load entering the proximal small intestine. Similar mechanisms appear to mediate bicarbonate secretion within the proximal small intestine. Consequently, the intraluminal environment is often well below the optimal pH for maximal pancreatic enzyme activity, and may hasten inactivation of enzymes (particularly lipase) within the small intestine44'45. 50 observed no improvement in steatorrhoea with cimetidine but the dose or the type of enzyme given was not specified.
Enteric coated microspheres Since the early 1 980s, a variety of enteric coated preparations have been used as the enzyme of choice in the treatment of pancreatic insufficiencys1. Some of the first attempts to protect the enzymes utilizing enteric coated tablets were ineffective. Due to their size, the tablets were selectively retained in the stomach and dissociated from the chyme entering the duodenum. When these tablets were crushed and repackaged into capsules, there was a concomitant improvement in fat maldigestion. Experience with other pharmaceutical products using coating of microspheres with various polymers led to the introduction of microspheres and/or microtablets of enzymes protected by a variety of acid resistant enteric coatings. It was argued that efficacy would be improved if the pancreatic enzymes were protected from the harsh acid-peptic environment of the stomach and greater quantities of active enzyme would be released into the more alkaline small intestine following dissolution of the protective coating. The general experience in the care of CF patients using the earlier enteric coated products (5000-8000 units of lipase/ capsule) appeared to suggest that patients could ingest fewer capsules and therefore less enzyme as a total daily dose52-59. Most published studies demonstrated that enteric coated products were of equal, or slightly superior efficacy, when the daily dose of an enteric product was approximately half that of an equipotent conventional enzyme product. In reality, many patients did not reduce the number of pills they were ingesting. Furthermore, some caregivers recommended that doses be increased, making the assumption that 'more is better', or that gastrointestinal symptoms can be controlled by higher doses of enzymes. A number of erroneous assumptions, as follows, appear to have been promulgated by caregivers and communicated to their patients. * Pancreatic enzymes are innocuous * The dose and potency of conventional enzymes were inadequate * All gastrointestinal symptoms in CF are due to pancreatic insufficiency * Improved nutritional status of patients with CF can be attributed to introduction of enteric coated enzyme products * Caregivers know what doses of enzymes their patients are taking * Patients with persistent steatorrhoea will benefit from higher potency enzymes * Enzymes given in higher doses will relieve gastrointestinal disease.
Consequently, when the more concentrated enzyme preparations (greater than 20 000 units lipase per capsule) were introduced in the early 1990s, there was an escalation in the total daily dose of ingested active enzymes in a number of centres. This resulted in a marked increase in global sales of pancreatic enzyme products. Regardless of the precise aetiology of fibrosing colonopathy, current epidemiological evidence shows a strong association between the daily dose of enzymes (both normal and high potency products), and the risk of this newly recognized complication3436.
The rapidity of dissolution of the protective enteric coating is influenced by the biochemical properties of the acid resistant coating, the size of the microsphere or microtablet (effect of surface area), the thickness of the protective coating and the intraluminal environment of the host. There is considerable in vitro variability in the optimal pH at which the protective coating dissolves from product to product39. As will be discussed below, the in vivo characteristics of the various products have not been adequately evaluated. For Once the microspheres or microtablet enters the small intestine, the coating is expected to dissolve, releasing active enzyme into the intestinal lumen to facilitate digestion. In health, digestion is essentially complete within that the enteric coating dissolutes in the duodenum or even the proximal jenunum. In alkaline pH conditions, in vitro, the coating takes up to 10-15 min to dissolve (Durie, unpublished) . Furthermore, in patients with CF, the relatively acidic intestinal environment may delay, or even prevent dissolution of the protective enzyme coating43-5. Theoretically, enzymes with an enteric coating that dissolves at a slightly acidic pH might be more efficacious. If the dissolution characteristics of the product approaches pH 4.0, however, there would be a tendency for the coating to dissolute within the stomach, effectively negating the objective of the protective coating. Most commercially available products have a polymeric coating that dissolves at a pH of between 5.2 and 6.039. Robinson et al.45 evaluated post prandial duodenal pH in children with CF and in agematched controls. In comparison with the controls, the patients with CF experienced significantly longer postprandial periods when the duodenal pH was below 4, which is known to be below the dissolution pH of the coating and also will irreversibly denature pancreatic lipase. Furthermore, the duodenum of the patients with CF had significantly less time above ph 5.8 which in turn suggests that the enteric coating would take longer to dissolve. This study demonstrated a significant direct relationship between the degree of residual fat maldigestion and duodenal pH levels. Similar observations were made in a study of 24-h ambulatory gastric and duodenal pH profiles in patients with CF44. Duodenal pH fell in the first post prandial hour and with successive meals duodenal pH became lower. However, the total time duodenal pH remained below 5 varied considerably from patient to patient. Thus, in theory, a product with a lower optimal pH for dissolution of the coating of approximately 5.0 would be expected to be more efficacious. In a double-blind cross-over study, we compared the efficacy of two protective coatings, each with a dissolution pH of 5.2 and 6.0, respectively60. In all other respects the two products were identical. Seventeen patients completed two randomly assigned treatment arms; 72-h stool collection were completed at the end of each period. We were surprised to discover that there was no difference in faecal weight, faecal energy or faecal fat with the two products. Thus, the product with a coating that dissolved at a lower pH appeared to offer no clear advantage61. Low Age (years) Figure 6 , a significant percentage of children, and particularly teenagers, admitted to poor compliance with enzymes: in several cases poor compliance occurred with alarming frequency. The results of this survey almost certainly underestimate the extent of the problem. Thus, it should be assumed that a significant percentage of children, Faecal fat (% of intake) Whenever there is doubt concerning efficacy of therapy, a 72-h fat balance study, while carefully recording enzyme and nutrient intake is indicated. As shown in Figure 7 the results are likely to be quite revealing. These data are a 3 
